

Milk Thistle (*Silybum marianum*)

Milk thistle is a well known and commonly used herb, used particularly in hepatic diseases. It has very potent antioxidant, anti-inflammatory, and antifibrotic properties (1). As a single agent its therapeutic effects in liver disease appear to be modest (2,3,4,5). Herbal medicines and supplements are likely to be much more beneficial when used synergistically in combinations or formulas. Milk thistle preparations have also shown promise *in vitro* in the treatment of malignancies. They have been shown to have beneficial cell cycle and antiangiogenic properties (6,7), and inhibition of telomerase activity (8). They have been tested in various tumor types with promising effects (7,8).

The use of any herb in oncology needs to be considered regarding potential drug-herb interactions. This is even more so in the case of an herb which is known to affect liver function. Various drug detoxifying functions occur primarily in the liver, such as the cytochrome p450 and phase 2 deconjugation reactions. In fact, milk thistle preparations have primarily been employed in conventional practice in cases of potential drug toxicity, such as with poisonous mushrooms and CCL4 with significant protection against hepatic failure.

Some studies have shown synergistic effects when milk thistle preparations have been studied in combination with chemotherapeutic agents. Singh studied silibinin (one of the main active components in milk thistle) in combination with doxorubicin and found enhanced activity in an athymic mice with lung tumors. Indexes of cell proliferation, angiogenesis and apoptosis showed benefit. Silibinin was shown to inhibit NFkB and COX -2, which are known to promote drug resistance (9). Bokemeyer studied silibinin in combination with cisplatin and amifostine in a rat germ tumor cell model, and found protection against nephrotoxicity and ototoxicity, as well as no evidence of a negative effect on the cytotoxicity of these agents. He suggested further study in patients with testicular cancer (10). No effect was found when a milk thistle preparation was administered with indinavir, an antiviral agent (11). Tyagi found synergism with doxorubicin, cisplatin and carboplatin in a breast cancer cell line (12). Specific studies on effects on the p450 and phase 2 deconjugation reactions have been mixed (13,14,15). Zhou noted a beneficial effect on P-Glycoprotein which is involved in multidrug resistance gene pathways, where milk thistle acted opposite to St. Johns Wort, an herb which has been shown to have worrisome drug-herb interactions (16).

As has been discussed in the section on antioxidants and malignancies, significant concern exists regarding potential negative interactions between antioxidants and chemotherapy and radiation therapy. There are rationale theoretical reasons behind this concern, though there is little in the way of evidence based medicine to support it. However, a different situation exists regarding the interaction of anti-inflammatory interventions used in conjunction with chemotherapy and radiation therapy. Various physiological processes, often involving NFkB and COX-2 enzymes, are upregulated when chemotherapy and radiotherapy are administered. The upregulation has the effect of decreasing the

effectiveness of these interventions. Herbs containing concentrated amounts of flavonoids have multiple effects, including being potent antioxidants and anti-inflammatory agents. The vast majority of the literature on these substances, which is confirmed in those studies cited above, suggests that these herbs enhance efficacy of chemotherapy and radiation therapy, as well as potentially decreasing adverse treatment reactions. If this occurs primarily through their anti-inflammatory effects isn't known.

Reducing free radicals through antioxidants also has an anti-inflammatory result, and it's physiologically entirely conceivable to expect that the antioxidant and antiinflammatory actions support each other. This might not be the case with the antioxidant vitamins beta-carotene and tocopherols when used in conjunction with chemotherapy and radiation therapy.

A range of milk thistle preparations exist, standardized to concentrations of different components, including silibinin and silymarin. In addition, a product which is pharmaceutically combined with phosphatidyl choline (known as IdB 1016 and available in the U.S. as silybin phytosome through the company Phytopharmica) appears to be particularly promising with regards to concentrations and potency (17). This is of great importance, as there are significant concerns regarding the bioavailability of flavonoid compounds. Therapeutic dosage is likely in the range of 300-500 mg of silibinin daily.

In summary:

- Milk thistle preparations have actions which can be of benefit in patients with different malignancies.
- Thistle flavonoids have both anti-oxidant and anti-inflammatory properties which may act synergistically in combination with certain chemotherapeutic agents, while at the same time providing hepatoprotective effects.
- Issues of dosage are important, and products which are combined with phosphatidyl choline, and are high in silibinin are particularly promising.

Bibliography

- 1) Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, Park HY, Kim KJ, Jeong KS. Alterations of mast cells and TGF- β 1 on the silymarin treatment for CCl₄-induced hepatic fibrosis. *World J Gastroenterol.* 11(8):1141-1148, February 28, 2005.
- 2) Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, Crepaldi G. Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease: Efficacy study of a new preparation of an anti-oxidant agent. *Diabetes Nutr Metab.* 15(4):222-31, August 2002.
- 3) Lieber CS. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. *Current Gastroenterology Reports.* 6:60-65, 2004.
- 4) Parés A, Planas R, Torres M, Caballería J, Viver JM, Acero D, Panés J, Rigau J, Santos J, Rodés J. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. *Journal of Hepatology.* 28(4):615-621, April 1998.

- 5) Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. *Drugs*. 61(14):2035-63, 2001.
- 6) Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. *Oncogene*. 24(7):1188-1202, February 10, 2005.
- 7) Gallo D, Giacomelli S, Ferlini C, Raspaglio G, Apollonio P, Prislei S, Riva A, Morazzoni P, Bombardelli E, Scambia, G. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. *European Journal of Cancer*. 39(16):2403-2410, November 2003.
- 8) Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. *J Urol*. 171(5):1934-8, May 2004.
- 9) Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. *Clin Cancer Res*. 10(24):8641-7, December 15, 2004.
- 10) Bokemeyer C, Fels LM, Dunn T, Voigt W, Gaedeke J, Schmoll HJ, Stolte H, Lentzen H. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. *Br J Cancer*. 74(12):2036-41, December 1996.
- 11) DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G. Coadministration of milk thistle and indinavir in healthy subjects. *Pharmacotherapy*. 23(7):866-70, July 2003.
- 12) Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. *Oncology Rep*. 11(2):493-9, February 2004.
- 13) Zuber R, Modriansky M, Dvorak Z, Rohovsky P, Ulrichova J, Simanek V, Anzenbacher P. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. *Phytotherapy Res*. 16(7):632-8, November 2002.
- 14) Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. *Clin Pharmacol Ther*. 76(5):428-40, November 2004.
- 15) Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. *Drug Metab Dispos*. 32(6):587-94, June 2004.
- 16) Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. *Drug Metab Rev*. 36(1):57-104, February 2004.
- 17) Schandalik, R, Gatti, G, Perucca, E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. *Arzneimittel-Forschung*. 42(7):964-968, July 1992.